Alpha-fetoprotein-to-PIVKA-II Ratio As a Potential Biomarker for Hepatocellular Carcinoma Differentiation, Imaging Characteristics, and Patient Survival

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2024 Dec 19

PMID 39697743

Authors

Menene Nkonika Dieu-Merci

Jihong Hu

Xinyi Fang

Renjie Zhao

Xiaojie Xie

Wenqiu Pan

Thapa Aayush

Fang Yin

Hu Xingyue

Dan Han

Affiliations

Soon will be listed here.

Abstract

Background: Alpha-fetoprotein-to-PIVKA-II ratio (APR) may serve as a new marker to predict the grade of differentiation, imaging characteristics, and prognosis of hepatocellular carcinoma (HCC). This study aimed to demonstrate the prognostic significance of high APR for poorly differentiated HCC (PD-HCC), imaging characteristics and overall survival (OS) in patients after intra-arterial therapies.

Methods: Receiver operating characteristic (ROC) curves were constructed and areas under the curve (AUCs) were calculated to evaluate the predictive ability of APR to discriminate subgroup(s) of HCC with good or poor prognosis. Kaplan-Meier survival analysis was performed to evaluate the effect of tumor differentiation and change in APR on overall patient survival.

Results: The cut-off value of APR used in the diagnostic setting was 0.175. Almost all patients in the PD-HCC group (90.9%) had a high APR value, while 100% and 84.2% of well-differentiated and moderately differentiated HCC (WD-HCC and MD-HCC) patients, respectively, had a low APR value (P<0.001). APR had a high sensitivity (91%) and specificity (90%) in differentiating PD-HCCs from WD-HCCs/MD-HCCs (P<0.001). Patients with high APR tended to have large and multiple tumors, vascular invasion and high percentage signal ratio (PSR). OS was slightly shorter in the PD-HCC group and in the high (>0.175) APR group.

Conclusions: This study showed that patients with high APR and those with PD-HCC had a worse prognosis, and APR could be an important non-invasive biomarker for predicting the degree of tumor differentiation, imaging characteristics and patient prognosis.

References

Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu M, Allen C . The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol. 2017; 3(12):1683-1691. PMC: 5824275. DOI: 10.1001/jamaoncol.2017.3055. View

Wu J, Xiang Z, Bai L, He L, Tan L, Hu M . Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA. Cancer Biomark. 2018; 23(2):235-242. DOI: 10.3233/CBM-181402. View

Reiser B . Measuring the effectiveness of diagnostic markers in the presence of measurement error through the use of ROC curves. Stat Med. 2000; 19(16):2115-29. DOI: 10.1002/1097-0258(20000830)19:16<2115::aid-sim529>3.0.co;2-m. View

Gotsman I, Israeli D, Alper R, Rabbani E, Engelhardt D, Ilan Y . Induction of immune tolerance toward tumor-associated-antigens enables growth of human hepatoma in mice. Int J Cancer. 2002; 97(1):52-7. DOI: 10.1002/ijc.1576. View

Parfitt J, Marotta P, Alghamdi M, Wall W, Khakhar A, Suskin N . Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl. 2007; 13(4):543-51. DOI: 10.1002/lt.21078. View

Zhou L, Rui J, Wang S, Chen S, Qu Q . Early recurrence in large hepatocellular carcinoma after curative hepatic resection: prognostic significance and risk factors. Hepatogastroenterology. 2015; 61(135):2035-41. View

Ma X, Zhu J, Wu J, Tian L, Gao Y, Zhang C . Significance of PIVKA-II levels for predicting microvascular invasion and tumor cell proliferation in Chinese patients with hepatitis B virus-associated hepatocellular carcinoma. Oncol Lett. 2018; 15(6):8396-8404. PMC: 5950517. DOI: 10.3892/ol.2018.8375. View

Cho E, Choi J . MRI features of hepatocellular carcinoma related to biologic behavior. Korean J Radiol. 2015; 16(3):449-64. PMC: 4435980. DOI: 10.3348/kjr.2015.16.3.449. View

Wang X, Zhang W, Liu Y, Gong W, Sun P, Kong X . Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma. Infect Agent Cancer. 2017; 12:47. PMC: 5569466. DOI: 10.1186/s13027-017-0153-6. View

10.

Zhang Q, Lou Y, Yang J, Wang J, Feng J, Zhao Y . Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas. Gut. 2019; 68(11):2019-2031. PMC: 6839802. DOI: 10.1136/gutjnl-2019-318912. View

11.

Ogihara Y, Kitazume Y, Iwasa Y, Taura S, Himeno Y, Kimura T . Prediction of histological grade of hepatocellular carcinoma using quantitative diffusion-weighted MRI: a retrospective multivendor study. Br J Radiol. 2017; 91(1084):20170728. PMC: 5965986. DOI: 10.1259/bjr.20170728. View

12.

Ho D, Tsui Y, Sze K, Chan L, Cheung T, Lee E . Single-cell transcriptomics reveals the landscape of intra-tumoral heterogeneity and stemness-related subpopulations in liver cancer. Cancer Lett. 2019; 459:176-185. DOI: 10.1016/j.canlet.2019.06.002. View

13.

Colecchia A, Schiumerini R, Cucchetti A, Cescon M, Taddia M, Marasco G . Prognostic factors for hepatocellular carcinoma recurrence. World J Gastroenterol. 2014; 20(20):5935-50. PMC: 4033434. DOI: 10.3748/wjg.v20.i20.5935. View

14.

Farmer D, Rosove M, Shaked A, Busuttil R . Current treatment modalities for hepatocellular carcinoma. Ann Surg. 1994; 219(3):236-47. PMC: 1243131. DOI: 10.1097/00000658-199403000-00003. View

15.

Yang T, Wei H, Wu Y, Qin Y, Chen J, Jiang H . Predicting histologic differentiation of solitary hepatocellular carcinoma up to 5 cm on gadoxetate disodium-enhanced MRI. Insights Imaging. 2023; 14(1):3. PMC: 9826771. DOI: 10.1186/s13244-022-01354-w. View

16.

Shinkawa H, Tanaka S, Kabata D, Takemura S, Amano R, Kimura K . The Prognostic Impact of Tumor Differentiation on Recurrence and Survival after Resection of Hepatocellular Carcinoma Is Dependent on Tumor Size. Liver Cancer. 2021; 10(5):461-472. PMC: 8527909. DOI: 10.1159/000517992. View

17.

Nguyen T, Phillips D, Jain D, Torbenson M, Wu T, Yeh M . Comparison of 5 Immunohistochemical Markers of Hepatocellular Differentiation for the Diagnosis of Hepatocellular Carcinoma. Arch Pathol Lab Med. 2015; 139(8):1028-34. DOI: 10.5858/arpa.2014-0479-OA. View

18.

Youden W . Index for rating diagnostic tests. Cancer. 1950; 3(1):32-5. DOI: 10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3. View

19.

Hu J, Gong N, Li D, Deng Y, Chen J, Luo D . Identifying hepatocellular carcinoma patients with survival benefits from surgery combined with chemotherapy: based on machine learning model. World J Surg Oncol. 2022; 20(1):377. PMC: 9714169. DOI: 10.1186/s12957-022-02837-2. View

20.

Kudo M . Multistep human hepatocarcinogenesis: correlation of imaging with pathology. J Gastroenterol. 2009; 44 Suppl 19:112-8. DOI: 10.1007/s00535-008-2274-6. View